Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
57
ANIK Quote, Financials, Valuation and Earnings
Last price:
$14.21
Seasonality move
:
12.8%
Day range:
$11.60 - $12.84
52-week range:
$7.87 - $17.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.63x
P/B ratio:
1.26x
Volume:
273.2K
Avg. volume:
150K
1-year change:
-27.7%
Market cap:
$184.4M
Revenue:
$119.9M
EPS (TTM):
-$2.28
Analysts' Opinion
-
Consensus RatingAnika Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Anika Therapeutics, Inc. has an estimated upside of 25.1% from its current price of $12.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $12.79.
Fair Value
-
According to the consensus of 1 analyst, Anika Therapeutics, Inc. has 25.1% upside to fair value with a price target of $16.00 per share.
ANIK vs. S&P 500
-
Over the past 5 trading days, Anika Therapeutics, Inc. has overperformed the S&P 500 by 19.54% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Anika Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Anika Therapeutics, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Anika Therapeutics, Inc. reported revenues of $27.8M.
Earnings Growth
-
Anika Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Anika Therapeutics, Inc. reported earnings per share of -$0.16.
Enterprise value:
151M
EV / Invested capital:
--
Price / LTM sales:
1.63x
EV / EBIT:
--
EV / Revenue:
1.34x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
232.97x
Price / Operating cash flow:
284.50x
Enterprise value / EBITDA:
18.87x
Gross Profit (TTM):
$61.8M
Return On Assets:
-7.03%
Net Income Margin (TTM):
-12.65%
Return On Equity:
-9.18%
Return On Invested Capital:
-7.88%
Operating Margin:
-11.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $163.3M | $119.5M | $112.8M | $29.6M | $27.8M | |
| Gross Profit | $100.9M | $79.5M | $61.8M | $19.4M | $15.6M | |
| Operating Income | -$30.5M | -$2.8M | -$12.4M | -$81K | -$3.2M | |
| EBITDA | -$14M | $3.6M | -$6.5M | $1.4M | -$1.8M | |
| Diluted EPS | -$1.68 | -$6.64 | -$2.28 | -$2.03 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $165.8M | $167.8M | $156.8M | $136.1M | $101.6M | |
| Total Assets | $352.9M | $347.7M | $328.2M | $231.4M | $189.4M | |
| Current Liabilities | $28.8M | $26.4M | $28.1M | $25.5M | $19.1M | |
| Total Liabilities | $62.9M | $62.8M | $57.7M | $51.5M | $42.6M | |
| Total Equity | $290.1M | $284.9M | $270.5M | $179.9M | $146.8M | |
| Total Debt | $19.6M | $29.2M | $27.3M | $25.2M | $22.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.9M | $7.5M | $8.1M | $5M | $6.9M | |
| Cash From Investing | -$6.1M | -$8.9M | -$1.9M | -$1.8M | -$1.7M | |
| Cash From Financing | -$6M | -$7M | -$10.6M | -$4M | -$13K | |
| Free Cash Flow | -$11.1M | -$1.4M | $648K | $3.2M | $5M | |
ANIK
Sector
Market Cap
$184.4M
$25.8M
Price % of 52-Week High
72.1%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
7.16%
-1.64%
1-Year Price Total Return
-27.7%
-18.88%
Beta (5-Year)
0.433
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.97
200-day SMA
Buy
Level
$9.94
Bollinger Bands (100)
Buy
Level
9.2 - 10.26
Chaikin Money Flow
Sell
Level
-4.2M
20-day SMA
Buy
Level
$10.42
Relative Strength Index (RSI14)
Buy
Level
82.94
ADX Line
Buy
Level
36.79
Williams %R
Sell
Level
-1.8474
50-day SMA
Buy
Level
$9.85
MACD (12, 26)
Buy
Level
0.48
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
22.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.756)
Buy
CA Score
(Annual)
Level (0.6909)
Buy
Beneish M-Score
(Annual)
Level (-2.8461)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.9815)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.
Stock Forecast FAQ
In the current month, ANIK has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ANIK average analyst price target in the past 3 months is $16.00.
-
Where Will Anika Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Anika Therapeutics, Inc. share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Anika Therapeutics, Inc.?
Analysts are divided on their view about Anika Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Anika Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Anika Therapeutics, Inc.'s Price Target?
The price target for Anika Therapeutics, Inc. over the next 1-year time period is forecast to be $16.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ANIK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Anika Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ANIK?
You can purchase shares of Anika Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Anika Therapeutics, Inc. shares.
-
What Is The Anika Therapeutics, Inc. Share Price Today?
Anika Therapeutics, Inc. was last trading at $14.21 per share. This represents the most recent stock quote for Anika Therapeutics, Inc.. Yesterday, Anika Therapeutics, Inc. closed at $12.79 per share.
-
How To Buy Anika Therapeutics, Inc. Stock Online?
In order to purchase Anika Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ANIK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANIK
Sector
P/E ratio
--
23.44x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.26x
1.81x
Price / LTM sales
1.63x
1.56x
Growth Metrics
ANIK
Sector
Revenue growth
-5.89%
3.27%
Earnings growth
92.03%
9.66%
Revenue (5-year growth)
0.91%
6.43%
Earnings forecast
$0.02
-$0.20
Profitability
ANIK
Sector
Profitability FY 2024
$76M
$2.3M
Return on invested capital
-7.88%
-33.49%
Return on assets
-7.03%
-29.74%
Return on equity
-9.18%
-39.33%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
Feb
27
Estimated Next Earnings Date
May
29
Balance Sheet
ANIK
Sector
Total cash
$58M
$24.2M
Short term investments
--
$23.8M
Total assets
$215.6M
$71.1M
Long term debt
$22.8M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.44% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 9.54% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
